Sparingvision
SparingVision is a clinical-stage genomic medicines company developing mutation-agnostic gene therapies for inherited retinal diseases and dry age-related macular degeneration. Its lead product, SPVN06, is a neuroprotective gene therapy designed to treat retinitis pigmentosa regardless of the specific genetic cause. The company aims to provide vision-saving treatments for patients affected by blinding retinal diseases and geographic atrophy.
Visit websiteParis, France
Healthtech
Biotechnology
Genomic Medicine
Ophthalmology
Funding summary
- Total raised
- €135.0M
- Funding rounds
- 3
Investors in Sparingvision
Investors on record for Sparingvision. Click any investor to view their CAPLINK profile and funding criteria.
Fundraising for a startup like Sparingvision?
Explore CAPLINK's investor database of thousands of active VCs and angels.
Browse investors